|
Volumn 80, Issue 9, 2001, Pages 521-524
|
Thiotepa and fludarabine (TT-FLUDA) as conditioning regimen in poor candidates for conventional allogeneic hemopoietic stem cell transplant
a a a a a a a a a a |
Author keywords
Allogeneic stem cell transplant; Conditioning regimen; Fludarabine; Thiotepa
|
Indexed keywords
ALANINE AMINOTRANSFERASE;
ANTILEUKEMIC AGENT;
ANTINEOPLASTIC AGENT;
ASPARTATE AMINOTRANSFERASE;
BUSULFAN;
CD16 ANTIGEN;
CD19 ANTIGEN;
CD3 ANTIGEN;
CD34 ANTIGEN;
CD4 ANTIGEN;
CD5 ANTIGEN;
CD56 ANTIGEN;
CD8 ANTIGEN;
CYCLOSPORIN A;
CYTARABINE;
DNA MINISATELLITE;
FLUDARABINE;
GRANULOCYTE COLONY STIMULATING FACTOR;
HLA ANTIGEN;
IDARUBICIN;
MELPHALAN;
METHOTREXATE;
STEROID;
THIOTEPA;
THYMOCYTE ANTIBODY;
ACUTE GRANULOCYTIC LEUKEMIA;
ADULT;
ALLOGENIC BONE MARROW TRANSPLANTATION;
ARTICLE;
BLOOD TRANSFUSION;
CANCER MORTALITY;
CANCER RECURRENCE;
CHEMOPROPHYLAXIS;
CHIMERA;
CLINICAL ARTICLE;
CLINICAL PROTOCOL;
CLINICAL TRIAL;
COMBINATION CHEMOTHERAPY;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DOSE TIME EFFECT RELATION;
DRUG TOLERABILITY;
FEMALE;
FLUORESCENCE IN SITU HYBRIDIZATION;
GRAFT VERSUS HOST REACTION;
HEMATOPOIETIC STEM CELL TRANSPLANTATION;
HUMAN;
IMMUNOSUPPRESSIVE TREATMENT;
LEUKEMIA REMISSION;
MALE;
MANTLE CELL LYMPHOMA;
NONHODGKIN LYMPHOMA;
POLYMERASE CHAIN REACTION;
PRIORITY JOURNAL;
REFRACTORY PERIOD;
RISK ASSESSMENT;
SEX CHROMOSOME;
SIDE EFFECT;
STEM CELL;
TESTIS CANCER;
TREATMENT PLANNING;
ADULT;
ANTINEOPLASTIC AGENTS, ALKYLATING;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
COMBINED MODALITY THERAPY;
FEMALE;
GRAFT REJECTION;
HEMATOLOGIC NEOPLASMS;
HEMATOPOIETIC STEM CELL TRANSPLANTATION;
HUMANS;
IMMUNOSUPPRESSIVE AGENTS;
MALE;
MIDDLE AGED;
THIOTEPA;
TRANSPLANTATION, HOMOLOGOUS;
TREATMENT OUTCOME;
VIDARABINE;
|
EID: 0034789233
PISSN: 09395555
EISSN: None
Source Type: Journal
DOI: 10.1007/s002770100344 Document Type: Article |
Times cited : (7)
|
References (18)
|